JP2007502265A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502265A5
JP2007502265A5 JP2006523069A JP2006523069A JP2007502265A5 JP 2007502265 A5 JP2007502265 A5 JP 2007502265A5 JP 2006523069 A JP2006523069 A JP 2006523069A JP 2006523069 A JP2006523069 A JP 2006523069A JP 2007502265 A5 JP2007502265 A5 JP 2007502265A5
Authority
JP
Japan
Prior art keywords
phenyl
dihydroxy
pyrrol
heptanoic acid
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006523069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002540 external-priority patent/WO2005014539A2/en
Publication of JP2007502265A publication Critical patent/JP2007502265A/ja
Publication of JP2007502265A5 publication Critical patent/JP2007502265A5/ja
Withdrawn legal-status Critical Current

Links

JP2006523069A 2003-08-11 2004-07-30 新規のピロールに基づいたHMG−CoA還元酵素阻害剤 Withdrawn JP2007502265A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49421603P 2003-08-11 2003-08-11
PCT/IB2004/002540 WO2005014539A2 (en) 2003-08-11 2004-07-30 Pyrrole-based hmg-coa reductase inhibitors

Publications (2)

Publication Number Publication Date
JP2007502265A JP2007502265A (ja) 2007-02-08
JP2007502265A5 true JP2007502265A5 (enExample) 2007-11-08

Family

ID=34135328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523069A Withdrawn JP2007502265A (ja) 2003-08-11 2004-07-30 新規のピロールに基づいたHMG−CoA還元酵素阻害剤

Country Status (7)

Country Link
US (1) US7250444B2 (enExample)
EP (1) EP1656132A2 (enExample)
JP (1) JP2007502265A (enExample)
BR (1) BRPI0413468A (enExample)
CA (1) CA2534494A1 (enExample)
MX (1) MXPA06001721A (enExample)
WO (1) WO2005014539A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2007042910A1 (en) * 2005-10-14 2007-04-19 Pfizer Products Inc. Imidazoles and their use as hmg-coa reductase inhibitors
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
ES2289945B1 (es) * 2006-07-21 2008-12-16 Ercros Industrial, S.A Procedimiento para la obtencion de dos intermedios avanzados y su uso para la obtencion de atorvastatina calcica amorfa.
SG10201506526QA (en) * 2007-12-21 2015-09-29 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
WO2009120783A1 (en) * 2008-03-25 2009-10-01 The Johns Hopkins University High affinity inhibitors of hepatitis c virus ns3/4a protease
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
WO2016122325A1 (en) 2015-01-30 2016-08-04 Rijksuniversiteit Groningen Methods for providing intermediates in the synthesis of atorvastatin.
JP2020502064A (ja) * 2016-11-29 2020-01-23 エピザイム,インコーポレイティド スルホン酸基を含むkat阻害剤としての化合物
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
CN108250194A (zh) * 2018-02-12 2018-07-06 李化绪 一种二氟苯并噻唑类化合物及其在降血脂药物中的应用
US12139461B1 (en) 2024-04-22 2024-11-12 King Saud University Piperidine compounds as PDE5 inhibitors
CN119462750A (zh) * 2025-01-08 2025-02-18 浙江先锋科技集团股份有限公司 一种阿托伐他汀钙衍生物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (enExample) 1974-06-07 1981-03-18
US4049495A (en) 1974-06-07 1977-09-20 Sankyo Company Limited Physiologically active substances and fermentative process for producing the same
US4137322A (en) 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS53147073A (en) 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
JPS5559180A (en) 1978-10-30 1980-05-02 Sankyo Co Ltd 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent
US4375475A (en) 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
AU598775B2 (en) 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
US4851427A (en) 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3722806A1 (de) 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
CA2417277A1 (en) * 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
US7078430B2 (en) 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors

Similar Documents

Publication Publication Date Title
JP2011502958A5 (enExample)
RU2356893C2 (ru) Ингибиторы фосфодиэстеразы 4
RU2315041C2 (ru) Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения
AR048306A1 (es) Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40
JP2014511869A5 (enExample)
JP2009507011A5 (enExample)
JP2007502806A5 (enExample)
JP2005536475A5 (enExample)
JP2018515555A5 (enExample)
JP2004520292A5 (enExample)
JP2008513515A5 (enExample)
RU2012132692A (ru) Новые ингибиторы s-нитрозоглутатионредуктазы
JP2010533722A5 (enExample)
JP2014502979A5 (enExample)
RU2009133259A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2010534647A5 (enExample)
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
JP2019507179A5 (enExample)
JP2012520867A5 (enExample)
CA2398794A1 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
JP2011505347A5 (enExample)
RU2012122056A (ru) Ингибиторы фермента диацилглицерин-о-ацилтрансферазы типа 1
JP2007505091A5 (enExample)
JP2023529011A5 (enExample)
RU2009148507A (ru) Производное тетрагидроизохинолин-1-она или его соль